Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
October 03, 2024 06:30 ET
|
Eton Pharmaceuticals
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to Bolster Eton’s Commercial Pediatric...
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
August 22, 2024 16:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 08, 2024 16:01 ET
|
Eton Pharmaceuticals
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew drug application (NDA) for ET-400 accepted...
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 30, 2024 17:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
July 15, 2024 16:05 ET
|
Eton Pharmaceuticals
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Eton Pharmaceuticals
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a...
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
May 01, 2024 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
April 30, 2024 07:00 ET
|
Eton Pharmaceuticals
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually --...
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
April 29, 2024 16:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and...
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
March 22, 2024 02:00 ET
|
Eton Pharmaceuticals
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024...